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Hemolytic-uremic syndrome (HUS) is a systemic disease
characterized by microvascular endothelial damage, mainly
in the gastrointestinal tract and the kidneys. A major cause of
HUS is Shiga toxigenic Escherichia coli (STEC) infection. In
addition to Shiga toxin, additional STEC virulence factors may
contribute to HUS. One is the newly discovered subtilase
cytotoxin (SubAB), which is highly toxic to eukaryotic cells,
and when injected intraperitoneally into mice causes
pathology resembling that associated with human HUS.
Recent data show that SubAB exhibits a strong preference for
glycans terminating in a2-3-linked N-glycolylneuraminic acid
(Neu5Gc), a sialic acid that humans are unable to synthesize,
because we genetically lack the necessary enzyme. However,
Neu5Gc can still be found on human cells due to metabolic
incorporation from the diet. Dietary incorporation happens
to be highest in human endothelium and to a lesser extent in
the intestinal epithelium, the two affected cell types in STEC-
induced HUS. Mammalian-derived foods such as red meat
and dairy products appear to be the primary source of
dietary Neu5Gc. Ironically, these are also common sources of
STEC contamination. Taken together, these findings suggest
a ‘two-hit’ process in the pathogenesis of human SubAB-
induced disease. First, humans eat Neu5Gc-rich food, leading
to incorporation of Neu5Gc on the surfaces of endothelial
and intestinal cells. Second, when exposed to a SubAB-
producing STEC strain, the toxin produced would be able to
bind to the intestinal epithelial cells, perhaps causing acute
gastrointestinal symptoms, and eventually damaging
endothelial cells in other organs like the kidney, thereby
causing HUS.
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HEMOLYTIC-UREMIC SYNDROME
Hemolytic-uremic syndrome (HUS) is a systemic disease
process characterized by microvascular endothelial damage
that occurs mainly in the gastrointestinal tract and in the
kidneys, and sometimes also in the brain and the liver. It
typically occurs in children younger than 5 years of age, but
may also occur in adults, and among the elderly. Non-
immune ‘microangiopathic’ hemolytic anemia, thrombo-
cytopenia, and acute renal failure caused by endothelial
damage are the principal clinical manifestations of severe
HUS, which sometimes follows an episode of bloody diarrhea
because of hemorrhagic colitis.1–4 HUS is thus subcategorized
into typical HUS (diarrhea-associated, or Dþ ) and atypical
(without diarrhea, or D). In the United States, about 90%
of the cases are classified as Dþ ,3 and we will therefore focus
on DþHUS and refer to it as just HUS in this article.
SHIGA TOXIGENIC E. coli, SHIGA TOXIN, AND HUS
The leading cause of HUS in North America and Western
Europe is considered to be gastrointestinal infection with
Shiga toxigenic E. coli (STEC), sometimes referred to as
enterohemorrhagic E. coli (EHEC). The capacity of STEC to
cause HUS1 has long been thought to be directly attributable
to the production of Shiga toxin (Stx), a member of the AB5
toxin family.4 The StxB subunits bind to the glycolipid
receptor, globotriaosylceramide (Gb3), triggering the uptake
of the holotoxin. The internalized StxA subunits have RNA-
N-glycosidase activity and inhibit host cell protein synthesis.
There are two major classes of Shiga toxin (Stx1 and Stx2),
which share B60% homology in both the A and B subunits.
STEC strains may produce either or both toxin types.
Pathogenesis of the human disease initially involves coloniza-
tion of the gut by STEC, without significant invasion of the
epithelium. Locally produced Stx is translocated across the
intestinal barrier and absorbed into the circulation. The toxin
then targets specific tissues in accordance with their expres-
sion of Gb3. In humans, Gb3 is found in highest concentra-
tions in the renal tubular epithelial cells and in microvascular
endothelial cells (particularly in the kidneys, gut, pancreas,
and brain), and damage at these sites is consistent with the
pathology of HUS. Microvascular and concomitant ischemic
damage to the intestinal wall also accounts for the severe
bloody diarrhea associated with STEC infection.4
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The STEC strains belong to over 200 E. coli O:H serotypes,
which vary in their capacity to cause HUS. The majority of
cases in Europe and North America are caused by O157:H7
strains, although other STEC serotypes may be underdetected
because of deliberate targeting of diagnostic strategies at
O157 strains. Differences in virulence between the STEC
strains may be because of the amount or subtype of Stx
produced (strains producing Stx2 are more virulent than Stx1
producers).4 However, many STEC associated with HUS
(including O157:H7) also carry the LEE (locus of enterocyte
effacement), which encodes the capacity to adhere intimately
and form attaching and effacing lesions on the enterocytes
(gut epithelial cells). Most STEC strains also carry large
(90–170 kb) plasmids, which encode several additional
putative accessory virulence factors.4
SUBTILASE CYTOTOXIN, A SECOND TOXIN IN STEC STRAINS
A more recently discovered and potentially important STEC
virulence factor is subtilase cytotoxin (SubAB). SubAB is the
prototype of a new and different AB5 toxin subfamily,
initially detected in a LEE-negative O113:H21 STEC strain
responsible for an outbreak of HUS in Australia.5,6 Despite
the absence of LEE, O113:H21 STEC are highly virulent and
such strains were, in fact, among the first STEC serotypes to
be causally associated with HUS.1 SubAB is highly toxic for
eukaryotic cells and its mechanism of action involves highly
specific A-subunit-mediated proteolytic cleavage of the
essential endoplasmic reticulum chaperone, BiP/GRP78.7
This triggers a massive endoplasmic reticulum stress
response, ultimately leading to apoptosis.8 Intraperitoneal
injection of purified SubAB in mice causes microangiopathic
hemolytic anemia, thrombocytopenia, and renal impairment,
characteristics typical of Stx-induced human HUS.9 Histolo-
gical examination of organs removed from SubAB-treated
mice revealed extensive microvascular thrombosis and other
histological damage in the brain, kidneys, and liver, as well as
dramatic splenic atrophy. Peripheral blood leukocytes were
increased at 24 h, and there was also significant neutrophil
infiltration in the liver, kidneys, and spleen, and toxin-
induced apoptosis was seen at these sites.9 These findings
indicate that SubAB also likely contributes to pathology in
humans.
The SubAB is known to be produced by a wide range of
STEC strains belonging to diverse O-serogroups, and there is
a strong association with strains that produce Stx2, but are
LEE-negative. It has been found in STEC isolates from
Australia, Europe, Japan, and America.10,11 At least in
O113:H21 strains, its operon (subAB) is carried on a self-
transmissible megaplasmid,5 thereby underscoring the po-
tential for further horizontal transfer to other E. coli
serogroups, or indeed to other Enterobacteriaceae.
SubAB GLYCAN RECEPTOR SPECIFICITY IS DIFFERENT FROM
Stx
Recent studies using glycan array, Biacore, and crystal-
lographic analyses indicate that the pentameric binding
subunit, SubB, exhibits strong specificity for glycan chains
terminating in a2-3-linked N-glycolylneuraminic acid
(Neu5Gc), a sialic acid (Sia) that humans are unable to
synthesize (see below). Interactions with otherwise iden-
tical glycans terminating in N-acetylneuraminic acid
(Neu5Ac), which differs by a single OH group, were more
than 10-fold weaker.12 The location of the glycan-binding
pocket on the sides of the SubB pentamer, rather than at
the base, as is the case for StxB,12 is also consistent with
recognition of glycans displayed on host cell glyco-
proteins rather than glycolipids. Indeed, many glycoproteins
express terminal a2-3-linked Sias on their N- and O-linked
glycans.13
EVOLUTIONARY LOSS OF Neu5Gc EXPRESSION IN HUMANS
The Sias are a family of nine-carbon backbone monosacchar-
ides that display wide diversity in nature, with more than 50
different variants presented in a variety of linkages, which are
often expressed in a cell-type-specific manner.13 Sias are
typically located at the outermost end of the so-called
‘glycocalyx’, a layer of glycoconjugates covering every cell.
Given this location, they are often used as key components of
receptors for pathogens and for some of their toxins. Of note,
Sias exist not only on the cell surface, but also on many
secreted soluble proteins, such as gut mucins and plasma
proteins, in which they could potentially function as
competitive inhibitors of pathogen or toxin binding to cell
surface Sias.13,14
In mammals, the most prevalent Sias are Neu5Ac and
Neu5Gc.13,14 The latter is formed by hydroxylation of CMP-
Neu5Ac in a complex enzymatic mechanism catalyzed by the
product of the Cmah gene. Although chimpanzees and all
other non-human hominids synthesize Neu5Gc, humans
cannot do so, because of a specific and human-universal
inactivating mutation in the Cmah gene.15
HUMAN CELLS CAN INCORPORATE DIETARY Neu5Gc
Human cells fed with free Sias can metabolically incorporate
and present them on their surfaces, as if they were made in
the same cell.16,17 Apparently, for this reason, small amounts
of Neu5Gc can still be found in humans because of metabolic
incorporation into the cells from the diet.16 Mammalian-
derived foods, such as red meats (lamb, pork, and beef) and
dairy products, seem to be the primary source of dietary
Neu5Gc.16 Neu5Gc incorporation is highest in the human
endothelium and to a lesser extent in the intestinal
epithelium, the two affected cell types in STEC-induced
HUS.16 It is thought that the endothelial incorporation
occurs over a long period of exposure to dietary Neu5Gc.
However, incorporation must happen over shorter periods
of time in the epithelial cells of the intestine,12,18 as these
cells have a turnover rate of just a few days. Regardless
of the kinetics, the Neu5Gc expression enhances the bind-
ing of SubAB to target tissues expressing them (see
examples in Figure 1). Further evidence was obtained by
showing that SubAB toxin binding to human tissues was
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blocked by a monospecific Chicken IgY antibody directed
against Neu5Gc and not by a control IgY antibody (see
Figure 1).
Neu5Gc SENSITIZES HUMAN CELLS TO SubAB, IN VITRO AND
IN VIVO
As SubAB binds to Neu5Gc with much higher affinity than
to Neu5Ac, we asked whether this could affect cell killing
in vitro. Indeed, when human cell lines were fed with Neu5Gc
or Neu5Ac, those incorporating Neu5Gc were killed at a
much lower toxin dose.12 Thus, dietary consumption of
Neu5Gc has the potential to similarly sensitize human
tissues to this toxin. In keeping with this, SubAB binds
directly to Neu5Gc-enriched cells on colon epithelial cells
and kidney glomerular endothelial cells in human tissue
sections.12 This binding was shown to be Neu5Gc-dependent,
as it was blocked by pre-incubation of the slides with
chicken anti-Neu5Gc IgY antibodies, but not with control
IgY preparations (Figure 1). Moreover, binding was markedly
lower when cells were treated with a SubAB derivative with
a single amino acid substitution in its B subunit that
abrogates binding to the OH group present in Neu5Gc, but
not in Neu5Ac.12
Neu5Gc AND IN VIVO SENSITIVITY TO SubAB
On the basis of our in vitro findings, we initially predicted
that wild-type C57Bl/6 mice would be more susceptible to
intraperitoneal challenge with purified SubAB than Cmah-
null mice. Surprisingly, these Neu5Gc-deficient mice died
somewhat earlier than the wild-type mice, with the toxicity
presumably being mediated by the weaker binding to
endogenous Neu5Ac-containing targets.12 The likely expla-
nation for this paradox is that Neu5Gc also exists in high
amounts on red blood cells and soluble serum proteins in
non-human mammals, such as chimpanzees and mice, that
have a functional Cmah gene product.19,20 These can act as a
‘sink’, soaking up the toxin and thereby protecting the
Neu5Gc-containing endothelial surfaces of the organism.
Further experiments substantiated this explanation, showing
that SubAB binding to Neu5Gc-containing glycans in gut
and kidney sections was blocked well by the serum from
chimpanzee and wild-type C57Bl/6 mice, but not by the
human or Cmah-null mouse serum.12 Thus, humans who
consume Neu5Gc-containing food, such as red meat, could be
particularly vulnerable to SubAB, not only because they load
Neu5Gc into gut epithelium and vascular endothelium gen-
erating high-affinity receptors for SubAB, but also because
















Figure 1 | Binding of subtilase cytotoxin (SubAB) to human intestine and kidney sections is dependent on the presence of
a2-3-linked N-glycolylneuraminic acid (Neu5Gc)-containing glycans. (a) Frozen sections of human colon were stained with chicken
anti-Neu5Gc or control IgY at 5 mg/ml followed by anti-chicken IgY-HRP (horseradish peroxidase) conjugate, and examined by
immunohistochemistry (bar¼ 100mm). (b) Similar human colon sections were overlaid with or without 1 mg/ml SubAB or SubABA12,
and the bound toxin was detected using rabbit anti-SubA and Cy3-labeled goat anti-rabbit IgG, and examined by epifluorescence
microscopy (bar¼ 50 mm). (c) Human colon sections were overlaid first with anti-Neu5Gc or control IgY at 5 mg/ml followed by 1 mg/ml
SubAB, and the bound toxin was detected as described in panel b. Background control sections received only rabbit anti-SubAB followed
by Cy3-labeled anti-rabbit IgG (Bar¼ 100 mm). (d) Human kidney sections were overlaid with 1 mg/ml SubAB or SubABA12, and in the
presence or absence of 10% human or chimpanzee serum, as indicated. Bound toxin was detected as described in panel b (bar¼ 50mm).
(From Byres et al.,12 Figure 3 panels (a-d), see original article for experimental details).
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they do not have any Neu5Gc-containing serum proteins that
could provide neutralizing protection against SubAB.20
LINKING HUS WITH SubAB AND Neu5Gc
Taken together, our findings are suggestive of a ‘two-hit’
process in the pathogenesis of SubAB-induced disease in
humans (Figure 2). The scenario is that humans first eat
Neu5Gc-rich foods, such as red meat and dairy products,
which leads to metabolic incorporation and presentation of
Neu5Gc on the surfaces of the endothelial cells and the
intestinal epithelia. When later exposed to a STEC strain that
produces SubAB, the toxin produced in the gastrointestinal
tract would be able to bind to the Neu5Gc-expressing
intestinal epithelial cells, perhaps causing acute gastrointest-
inal symptoms. This effect may be potentiated by the fact that
soluble human intestinal mucus is also likely to be poor in
Neu5Gc, and unlike mucus of other animals, it cannot act as
a local decoy. Furthermore, in the absence of serum with
protective Neu5Gc-containing glycoproteins, any SubAB
absorbed into the circulation would easily target the high-
affinity Neu5Gc-glycan receptors on the endothelial cell
surfaces, setting off the cascade of microangiopathic events
that are manifested as HUS.
One way to test this hypothesis in mice would be to
feed Cmah-null mice Neu5Gc to incorporate it onto the
epithelial and endothelial cells, and thereafter challenge these
mice with SubAB. However, because of yet unknown
metabolic differences between mice and humans, we have
so far been unable to get a human-like level of Neu5Gc
incorporation into the Cmah-null mice.19 This interesting
difference could be related to the fact that humans lost the
ability to synthesize Neu5Gc more than 2 million years ago.
Thus, it is possible that unlike mice, humans have lost the
ability to degrade Neu5Gc, once it is incorporated into cells.
Furthermore, directly addressing the role of SubAB and
dietary Neu5Gc in human disease epidemiologically would,
of course, be very complicated. Human challenge studies with
either purified SubAB or with SubAB-producing STEC are
out of the question. Examination of the incidence and/or
severity of HUS in vegans versus meat-eaters would also be
difficult because of the low overall incidence of STEC
infection, the fact that not all STEC produce SubAB, and
that as it is a newly discovered toxin, few clinical laboratories
have the capacity to detect its presence in STEC isolates.
Hence, more studies on how to further humanize the mouse
model are needed.
POETIC JUSTICE FOR RED MEAT EATERS?
Assuming that the ‘two-hit’ scenario shown in Figure 2





























Figure 2 | Humans who eat foods rich in the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc), can become susceptible to
food poisoning by the Neu5Gc-preferring subtilase cytotoxin (SubAB) toxin. Dietary intake of Neu5Gc-rich foods, such as red meats
and dairy products, can result in metabolic incorporation and display of Neu5Gc on glycoconjugates on the microvascular endothelial cells
in the kidney glomeruli and elsewhere, as well as on the surface of the gut epithelial cells. This process can generate
high-affinity receptors for SubAB on the cell surface. The very same foods happen to be the commonest source of Shiga toxigenic
E. coli (STEC) bacteria, including those strains capable of producing SubAB. STEC infection caused by consumption of contaminated
food will result in toxin production in the gastrointestinal tract. The toxin could then bind to the Neu5Gc-containing receptors on the
gut epithelium and cause gastrointestinal symptoms. This may also allow the toxin to be better absorbed systemically, and the lack
of competing Neu5Gc-glycoproteins in human serum would then allow maximal binding of SubAB to high-affinity receptors on
the endothelium in organs, such as the kidney, thereby triggering hemolytic-uremic syndrome (HUS) (based on Supplementary Figure 1
from Byres et al.12).
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Neu5Gc-rich foods not only sensitizes human tissues to
SubAB, but also simultaneously increases the likelihood of
infection with SubAb-expressing STEC. These pathogens are
usually found in the intestines of livestock, particularly cattle,
and most commonly enter the human food chain by fecal
contamination of red meat and dairy products during pro-
cessing4 (Figure 2). Thus, those who consume large amounts
of these types of foods may be unwittingly preparing their
bodies for damage by a SubAB-producing organism that
contaminates their next meal of the same food types.
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